Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR13047] to RING1 - BSA and Azide free
  • Suitable for: ICC, IP, WB, IHC-P
  • Knockout validated
  • Reacts with: Human

Overview

  • Product name

    Anti-RING1 antibody [EPR13047] - BSA and Azide free
    See all RING1 primary antibodies

  • Description

    Rabbit monoclonal [EPR13047] to RING1 - BSA and Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: ICC, IP, WB, IHC-Pmore details
    Unsuitable for: Flow Cyt

  • Species reactivity

    Reacts with: Human
    Predicted to work with: Dog, Chimpanzee, Rhesus monkey, Gorilla

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • Human endometrial carcinoma and pancreas tissues. Ramos, MOLT4, LNCaP and HeLa whole cell lysate (ab150035). HeLa cells.

  • General notes

    ab250174 is the carrier-free version of ab180170.

    Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.

    This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with

    This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Properties

Images

  • Immunoprecipitation - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    Immunoprecipitation - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)

    This data was developed using ab180170, the same antibody clone in a different buffer formulation.

    RING1 was immunoprecipitated from 0.35 mg HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate 10 ug with ab180170 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab180170 at 1/2000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/10000 dilution.

    Lane 1: HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate 10 ug

    Lane 2: ab180170 IP in HeLa whole cell lysate

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab180170 in mouse cerebellum tissue lysate

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 15 seconds

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)

    This data was developed using ab180170, the same antibody clone in a different buffer formulation.

    Immunohistochemical analysis of paraffin-embedded Human endometrial carcinoma tissue labeling RING1 using ab180170 at 1/50 dilution. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
  • Western blot - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    Western blot - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)

    This data was developed using ab180170, the same antibody clone in a different buffer formulation.

    Lane 1: Wild-type HAP1 cell lysate (20 µg)

    Lane 2: RING1 knockout HAP1 cell lysate (20 µg)

    Lane 3: MOLT4 cell lysate (20 µg)

    Lane 4: LnCaP cell lysate (20 µg)

    Lanes 1 - 4: Merged signal (red and green). Green - ab180170 observed at 52 kDa. Red - loading control, ab8245, observed at 37 kDa.

    ab180170 was shown to specifically react with RING1 when RING1 knockout samples were used. Wild-type and RING1 knockout samples were subjected to SDS-PAGE. ab180170 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

  • Western blot - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    Western blot - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    All lanes : Anti-RING1 antibody [EPR13047] (ab180170) at 1/5000 dilution

    Lane 1 : Ramos (human Burkitt's lymphoma) whole cell lysate
    Lane 2 : MOLT-4 (human acute lymphoblastic leukemia) whole cell lysate
    Lane 3 : LNCaP (Human prostate carcinoma) whole cell lysate
    Lane 4 : HeLa (human cervix adenocarcinoma) whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/2000 dilution

    Predicted band size: 42 kDa
    Observed band size: 50 kDa
    why is the actual band size different from the predicted?



    This data was developed using ab180170, the same antibody clone in a different buffer formulation.

    Blocking and dilution buffer: 5% NFDM/TBST.

    Exposure times: 

    Lanes 1-3: 3 minutes;

    Lane 4: 1 minute.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    This data was developed using ab180170, the same antibody clone in a different buffer formulation.Immunohistochemical analysis of paraffin-embedded Human pancreas tissue labeling RING1 using ab180170 at 1/50 dilution. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
  • Immunocytochemistry - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    Immunocytochemistry - Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    This data was developed using ab180170, the same antibody clone in a different buffer formulation.Immunofluorescence analysis of HeLa cells labeling RING1 using ab180170 at 1/50 dilution.
  • Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)
    Anti-RING1 antibody [EPR13047] - BSA and Azide free (ab250174)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

© 2021 Astana Biomed Group LLP. All rights reserved.